Source: MarketersMedia

Press Release: OrganiGram : Organigram Holdings Shares Climb as Canada Cannabis Legalization Draws Near

NEW YORK, NY / ACCESSWIRE / May 31, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is initiating coverage on Organigram Holdings, Inc. (OTCQB: OGRMF), a company who through its wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram's facility is located in Moncton, New Brunswick and Organigram is regulated by the Access to Cannabis for Medical Purposes Regulations.Adult recreational use of cannabis in Canada is expected to be legalized in the summer of 2018. The company's shares have jumped over 40% since April as the legalization date draws nearer.Read this report to see the company outlook for 2018 and the results for Q2 READ MORE.Copy and paste to your browser may be required to view the report - Holdings announced that it has entered into a letter of intent with Hyasynth Biologicals, Inc. whereby Organigram proposes to make a strategic investment in Hyasynth. Additionally, the non-binding letter of intent contemplates Organigram entering into an off-take agreement with Hyasynth whereby Organigram can purchase a pre-defined quantity of a range of cannabinoids or cannabinoid related production from Hyasynth.Get the recent company events and some product lines by Organigram READ MORE.Copy and paste to your browser may be required to view the report - News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.TNS has not been compensated; directly or indirectly; for producing or publishing this document.PRESS RELEASE PROCEDURESThe non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email [email protected] Vikas Agrawal, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.NO WARRANTYTNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.NOT AN OFFERINGThis document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: [email protected]® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.CONTACT:[email protected]: Traders News SourceReleaseID: 501285

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue


Gregory Engel's photo - CEO of Organigram


Gregory Engel

CEO Approval Rating


Organigram is a producer and marketer of medical cannabis for patients and physicians.

Organigram's headquarters is locat...
Read more